Iterum Therapeutics Plc (ITRM) Tops Q1 EPS by 44c

Iterum Therapeutics Plc (NASDAQ: ITRM) reported Q1 EPS of ($0.90), $0.44 better than the analyst estimate of ($1.34).

"During this challenging time, it is more important than ever to avoid hospitalization. We believe sulopenem, as potentially the first and only oral and IV penem antibiotic, will provide physicians the confidence and flexibility to treat their patients in a community setting. Should hospitalization be required, sulopenem can also be used as a step-down therapy allowing patients to leave the hospital sooner thereby reducing the risk of hospital-acquired infections, which is a benefit for patients, their families, and the over-stressed healthcare system,” said Corey Fishman, Chief Executive Officer of Iterum Therapeutics. “We expect to share topline results from our complicated urinary tract infection (cUTI) trial this month and topline results from our uncomplicated urinary tract infection (uUTI) trial shortly thereafter within the second quarter.”

For earnings history and earnings-related data on Iterum Therapeutics Plc (ITRM) click here.

You May Also Be Interested In

• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• Wealthfront launches custodial account with tax-gain harvesting
• Worthington Enterprises raises dividend 5%, adds board member